申请人:TRINITY COLLEGE DUBLIN
公开号:WO2001058904A1
公开(公告)日:2001-08-16
The invention relates to a pharmaceutical composition comprising an apoptosis-inducing amount of a compound having general formula (I), wherein: (i) R1 represents an unsubstituted C6 or C10 aryl group; or a C6 aryl group substituted with Me or OMe; (ii) A represents O, S or S partially oxidized to sulfoxide; (iii) the cyclic group labelled F represents an unsubstituted C6 or C10 aryl-fused group or a C5 heteroaryl-fused group (nitrogen as heteroatom) or a benzo-fused system substituted with ethoxycarbonyl function; (iv) and Y represents the group (A) wherein R2 and R3 are independently hydrogen; or methyl; or Y represents the group CH3 or a (CH2)2CH3 group; or an unsubstituted C5 heteroaryl group (nitrogen as heteroatom). The compositions may be used for the treatment of tumours or other cancerous conditions, such as CML (chronic myeloid leukaemia), AML, in AIDS-related lymphomas (such as Karpowski's sarcoma, a sub-cutaneous lymphoma) and used as apoptotic agents in the treatment of cancers generally.
本发明涉及一种药物组合物,包含一定量的通式(I)化合物,其诱导细胞凋亡的作用,其中:(i)R1代表未取代的C6或C10芳基;或取代有Me或OMe的C6芳基;(ii)A代表O,S或部分氧化为亚砜的S;(iii)标记为F的环状基团代表未取代的C6或C10芳基融合基团或取代有乙氧羰基的苯融合系统或C5杂环芳基融合基团(杂原子为氮);(iv)Y代表基团(A),其中R2和R3独立地代表氢;或甲基;或Y代表基团CH3或(CH2)2CH3基团;或未取代的C5杂环芳基(杂原子为氮)。该组合物可用于治疗肿瘤或其他癌症疾病,如慢性髓性白血病(CML)、急性髓性白血病(AML)、艾滋病相关淋巴瘤(如卡波夫斯基肉瘤,一种皮下淋巴瘤)并可作为凋亡剂用于治疗各种癌症。